Patents by Inventor Anne-Marie Lademann
Anne-Marie Lademann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220193046Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: August 4, 2021Publication date: June 23, 2022Inventors: Robert D Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 11123331Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: October 30, 2020Date of Patent: September 21, 2021Assignee: VELOXIS PHARMACEUTICALS, INC.Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 11110081Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: October 30, 2020Date of Patent: September 7, 2021Assignee: VELOXIS PHARMACEUTICALS, INC.Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20210046055Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: October 30, 2020Publication date: February 18, 2021Inventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
-
Publication number: 20210046054Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: October 30, 2020Publication date: February 18, 2021Inventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
-
Patent number: 10864199Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: February 11, 2016Date of Patent: December 15, 2020Assignee: VELOXIS PHARMACEUTICALS A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 9694080Abstract: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.Type: GrantFiled: August 23, 2013Date of Patent: July 4, 2017Assignee: EGALET LTD.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann, Christine Andersen
-
Publication number: 20160243091Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: February 11, 2016Publication date: August 25, 2016Inventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
-
Publication number: 20140179731Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: December 26, 2013Publication date: June 26, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20140120164Abstract: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.Type: ApplicationFiled: August 23, 2013Publication date: May 1, 2014Applicant: EGALET LTD.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann, Christine Andersen
-
Patent number: 8685998Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: July 7, 2009Date of Patent: April 1, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 8664239Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: June 23, 2011Date of Patent: March 4, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 8617605Abstract: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.Type: GrantFiled: March 7, 2008Date of Patent: December 31, 2013Assignee: Egalet Ltd.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann, Christine Andersen
-
Patent number: 8449914Abstract: A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(?) carvedilol for obtaining the desired therapeutic effect.Type: GrantFiled: March 13, 2008Date of Patent: May 28, 2013Assignee: Egalet Ltd.Inventors: Christine Andersen, Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
-
Patent number: 8298581Abstract: A controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200° C.Type: GrantFiled: March 26, 2004Date of Patent: October 30, 2012Assignee: Egalet A/SInventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
-
Publication number: 20120029009Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: June 23, 2011Publication date: February 2, 2012Applicant: LifeCycle Pharma A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20110275659Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: June 23, 2011Publication date: November 10, 2011Applicant: LifeCycle Pharma A/SInventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
-
Publication number: 20100166866Abstract: A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200° C.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
-
Publication number: 20100105717Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: July 7, 2009Publication date: April 29, 2010Applicant: LifeCycle Pharma A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20080268057Abstract: A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(?) carvedilol for obtaining the desired therapeutic effect.Type: ApplicationFiled: March 13, 2008Publication date: October 30, 2008Inventors: Christine Andersen, Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann